◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

Home › All stocks › AXSM

Axsome Therapeutics Inc (AXSM) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · BIOTECHNOLOGY · DATA UPDATED 2026-07-25

Axsome Therapeutics Inc (AXSM) operates in the BIOTECHNOLOGY industry and is headquartered in New York, United States with about 1,220 employees. Its market capitalization is roughly $12 billion. In the fiscal year ended 2025-12-31, AXSM reported $638M in revenue and ($183M) in net income.

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.

Interactive charts & full statements → Open the AXSM valuation workbench →

AXSM Revenue & Earnings History — Annual Income Statement

Income statement	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Revenue	$708M	$638M	$386M	$271M	$50M	$9M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—
Gross Profit	$656M	$591M	$352M	$245M	$45M	($1M)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	—
Gross Margin %	92.6%	92.6%	91.4%	90.4%	89.6%	-13.1%	—	—	—	—	—	—	—	—
Operating Income (EBIT)	($176M)	($169M)	($281M)	($232M)	($180M)	($125M)	($99M)	($67M)	($33M)	($27M)	($28M)	($9M)	($6M)	($2M)
Operating Margin %	-24.8%	-26.5%	-72.7%	-85.7%	-359.3%	-1414.0%	—	—	—	—	—	—	—	—
Net Income	($188M)	($183M)	($287M)	($239M)	($187M)	($135M)	($103M)	($68M)	($31M)	($29M)	($27M)	($12M)	($6M)	($2M)
Net Margin %	-26.6%	-28.7%	-74.5%	-88.4%	-374.0%	-1530.0%	—	—	—	—	—	—	—	—
EBITDA	($173M)	($168M)	($273M)	($225M)	($175M)	($124M)	($100M)	($67M)	($33M)	($28M)	($28M)	($9M)	($3M)	($2M)
Earnings Per Share (EPS)	$-3.74	$-3.68	$-5.99	$-5.27	$-4.60	$-3.59	$-2.77	$-2.01	$-1.15	$-1.27	$-1.42	$-1.02	$-0.47	$-0.28
Shares Outstanding (M)	51M	50M	48M	45M	41M	38M	37M	34M	27M	23M	19M	12M	13M	8M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AXSM Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Total Revenue	$191M	$196M	$171M	$150M	$121M	$119M	$105M	$87M
Gross Profit	$176M	$184M	$159M	$137M	$112M	$108M	$96M	$79M
Gross Margin %	92.3%	93.7%	93.0%	91.0%	91.9%	91.1%	92.0%	90.8%
Operating Income (EBIT)	($63M)	($29M)	($46M)	($37M)	($57M)	($73M)	($63M)	($78M)
Operating Margin %	-33.1%	-15.0%	-27.0%	-24.5%	-46.9%	-61.1%	-59.8%	-89.5%
Net Income	($65M)	($29M)	($47M)	($48M)	($59M)	($75M)	($65M)	($79M)
Net Margin %	-33.8%	-14.6%	-27.6%	-32.0%	-48.9%	-63.1%	-61.7%	-91.0%
EBITDA	($61M)	($25M)	($44M)	($43M)	($55M)	($71M)	($61M)	($76M)
Earnings Per Share (EPS)	$-1.26	$-0.56	$-0.94	$-0.97	$-1.22	$-1.54	$-1.34	$-1.67
Shares Outstanding (M)	51M	51M	50M	49M	49M	49M	48M	48M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AXSM Free Cash Flow History

Cash flow	TTM → 2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Cash from Operations (CFO)	($71M)	($93M)	($128M)	($145M)	($117M)	($108M)	($78M)	($46M)	($30M)	($26M)	($21M)	($7M)	($5M)	($2M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$1M	$1M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($71M)	($94M)	($129M)	($146M)	($117M)	($109M)	($79M)	($46M)	($30M)	($26M)	($21M)	($7M)	($5M)	($2M)
FCF Margin %	-10.0%	-14.7%	-33.4%	-53.8%	-234.2%	-1230.6%	—	—	—	—	—	—	—	—
Dividends Paid	—	—	—	—	$44M	—	—	—	—	$0M	$0M	—	—	—

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AXSM Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30
Cash from Operations (CFO)	($21M)	($19M)	$1M	($32M)	($43M)	($26M)	($19M)	($30M)
Capital Expenditures (CapEx)	$0M	$0M	$0M	$0M	$0M	$0M	$0M	$0M
Free Cash Flow (FCF)	($21M)	($19M)	$1M	($32M)	($44M)	($26M)	($19M)	($30M)
FCF Margin %	-10.9%	-9.6%	0.6%	-21.6%	-36.0%	-22.1%	-17.9%	-34.6%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

AXSM Balance Sheet History

Balance sheet	2026-03-31	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31
Total Assets	$714M	$690M	$568M	$588M	$331M	$88M	$186M	$221M	$15M	$36M	$38M	$49M	$3M	$2M
Cash & Cash Equivalents	$305M	$323M	$315M	$386M	$201M	$86M	$184M	$220M	$14M	$34M	$37M	$48M	$3M	$2M
Total Liabilities	$659M	$602M	$511M	$397M	$222M	$72M	$72M	$42M	$14M	$19M	$17M	$3M	$6M	$4M
Total Debt (Short + Long-Term)	$192M	$191M	$184M	$179M	$95M	$50M	$50M	$20M	$7M	$10M	$10M	$0M	$4M	$4M
Total Shareholders' Equity	$55M	$88M	$57M	$191M	$110M	$16M	$114M	$179M	$1M	$17M	$22M	$46M	($3M)	($2M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive AXSM viewer.

Other Companies in BIOTECHNOLOGY

BBIO · BridgeBio Pharma Inc — $16 billion
JAZZ · Jazz Pharmaceuticals PLC — $16 billion
EXEL · Exelixis Inc — $14 billion
MDGL · Madrigal Pharmaceuticals Inc — $13 billion
ARWR · Arrowhead Pharmaceuticals Inc — $12 billion
SMMT · Summit Therapeutics PLC — $12 billion
CYTK · Cytokinetics Inc — $12 billion
BMRN · Biomarin Pharmaceutical Inc — $11 billion

← AXS All stocks AXTA →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.